COMMUNIQUÉS West-GlobeNewswire

2024 Canada Gairdner Awards Recognize World-Renowned Scientists for Transformative Contributions to Research Impacting Human Health
11/04/2024
TORONTO, April 11, 2024 (GLOBE NEWSWIRE) -- The Gairdner Foundation is pleased to announce the 2024 Canada Gairdner Award laureates, recognizing some of the world’s most significant biomedical and global health research [...]
LES PRIX CANADA GAIRDNER 2024 RECONNAISSENT DES SCIENTIFIQUES DE RENOMMÉE MONDIALE POUR DES CONTRIBUTIONS TRANSFORMATRICES À LA RECHERCHE AYANT UN IMPACT SUR LA SANTÉ HUMAINE
11/04/2024
TORONTO, 11 avr. 2024 (GLOBE NEWSWIRE) -- La Fondation Gairdner est heureuse d’annoncer les lauréats des Prix Canada Gairdner 2024, reconnaissant certaines des recherches et des découvertes biomédicales et en santé [...]
AVITA Medical Updates Expected First Quarter 2024 Revenue
10/04/2024
VALENCIA, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin [...]
BrightSpring Health Services Specialty Pharmacy Onco360® Selected as National Pharmacy Partner for Voydeya®
10/04/2024
LOUISVILLE, Ky., April 10, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) announced today that its company Onco360 ® , a leading independent [...]
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
10/04/2024
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]
Cellectis publie une nouvelle approche d'édition intronique pour le traitement des maladies métaboliques congénitales par des cellules souches hématopoïétiques modifiées
10/04/2024
NEW YORK, 10 avr. 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome TALEN ® pour développer [...]
PharmAla Announces Private Placement and Concurrent Debt Settlement
10/04/2024
VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, [...]
Voting Rights and Shares Capital of the Company
10/04/2024
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, April 10, 2024 (GLOBE NEWSWIRE [...]
Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
10/04/2024
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 10 avr. 2024 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext [...]
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
10/04/2024
RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, is currently enrolling End-of-Phase 2 meeting scheduled to discuss development plan of deucrictibant for the [...]
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
10/04/2024
ZUG, Switzerland, April 10, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema [...]
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024
10/04/2024
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its [...]
Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
10/04/2024
FOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product [...]
Epic Bio to Participate in a Fireside Chat at the Canaccord Genuity Genetic Medicine for Generalists
10/04/2024
SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Epic Bio , a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced that Amber Salzman, Ph.D., [...]
New Nextech Med Spa for Wellness and Weight Loss Software Increases Average Patient Encounter Revenue by 70%
10/04/2024
TAMPA, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- Nextech, market leader of comprehensive technology solutions for specialty practices, has announced the launch of Nextech Med Spa for Wellness and Weight Loss with [...]
Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program : Eleventh tranche fully issued and paid-up
10/04/2024
Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program Eleventh tranche fully issued and paid-up Leuven, BELGIUM, 10 April 2024 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a [...]
Data Presented at AACR 2024 Showcase Precede Biosciences’ Power to Impact Precision Medicine from a Simple Blood Test
10/04/2024
Data further underscore potential to inform therapy selection for antibody drug conjugates and other target-directed therapies across breast, lung, and gastro-esophageal cancers Targets revealed from a single 1mL plasma [...]
Raydiant Oximetry Secures FDA Approval for Lumerah Investigational Device Exemption (IDE) Study
10/04/2024
SAN RAMON, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Raydiant Oximetry, Inc. , a clinical-stage medical device company that develops medical technologies to improve outcomes for mothers and babies during childbirth, [...]
OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer
10/04/2024
OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer Nantes, France – April 10, 2024 – 6:00 pm CET – OSE Immunotherapeutics [...]

Pages